Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%

Tumour response · people with cutaneous melanoma

Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.36 [1.12, 1.66]
770 participants
High

Tumour response · people with cutaneous melanoma

Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.27 [1.02, 1.58]
1885 participants
Moderate

Tumour response · people with cutaneous melanoma

Anti‐angiogenic drugs plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.71 [0.96, 3.03]
324 participants
Moderate

Tumour response · people with cutaneous melanoma

Anti‐CTLA4 monoclonal antibodies plus chemotherapy showed no clear difference in tumour response compared with chemotherapy (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.77]
1157 participants
Moderate

Tumour response · people with cutaneous melanoma

BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 6.78 [4.84, 9.49]
925 participants
High

Tumour response · people with cutaneous melanoma

MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 2.01 [1.35, 2.99]
496 participants
High

Tumour response · people with cutaneous melanoma

Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 3.42 [2.38, 4.92]
1367 participants
High